Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 14;25(20):11029.
doi: 10.3390/ijms252011029.

Lipoprotein (a) as a Cardiovascular Risk Factor in Controversial Clinical Scenarios: A Narrative Review

Hesham M Abdalla  1 , Ahmed K Mahmoud  2 , Ahmed E Khedr  3 , Juan M Farina  2 , Isabel G Scalia  2 , Mohammed Tiseer Abbas  2 , Kamal A Awad  2 , Nima Baba Ali  2 , Nadera N Bismee  2 , Sogol Attaripour Esfahani  2 , Niloofar Javadi  2 , Milagros Pereyra  2 , Said Alsidawi  2 , Steven J Lester  2 , Chadi Ayoub  2 , Reza Arsanjani  2
Affiliations
Review

Lipoprotein (a) as a Cardiovascular Risk Factor in Controversial Clinical Scenarios: A Narrative Review

Hesham M Abdalla et al. Int J Mol Sci. .

Abstract

Lipoprotein (a) is a complex lipid molecule that has sparked immense interest in recent years, after studies demonstrated its significant association with several cardiovascular conditions. Lp(a) promotes cardiovascular disease through its combined proatherogenic, pro-inflammatory, and prothrombotic effects. While the measurement of Lp(a) has become widely available, effective methods to reduce its concentration are currently limited. However, emerging data from ongoing clinical trials involving antisense oligonucleotides have indicated promising outcomes in effectively reducing Lp(a) concentrations. This may serve as a potential therapeutic target in the management and prevention of myocardial infarction, calcific aortic stenosis, and cerebrovascular accidents. In contrast, the role of Lp(a) in atrial fibrillation, in-stent restenosis, cardiac allograft vasculopathy, and bioprosthetic aortic valve degeneration remains unclear. This review article aims to thoroughly review the existing literature and provide an updated overview of the evidence surrounding the association of Lp(a) and these cardiovascular diseases. We seek to highlight controversies in the existing literature and offer directions for future investigations to better understand Lp(a)'s precise role in these conditions, while providing a summary of its unique molecular characteristics.

Keywords: atrial fibrillation; bioprosethetic aortic valve degeneration; cardiac allograft vasculopathy; in-stent restenosis; lipoprotein(a).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The association of Lipoprotein (a) with atrial fibrillation, in-stent restenosis, cardiac allograft vasculopathy, and bioprosthetic aortic valve degeneration.
Figure 2
Figure 2
Coronary catheterization images demonstrating left anterior descending artery in-stent restenosis identified in a patient with elevated Lp(a), four years post-stent placement. The circled area highlights the region of restenosis, evidenced by reduced contrast flow through the stented segment.
See this image and copyright information in PMC

References

    1. Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K., Blaha M.J., Cushman M., Das S.R., De Ferranti S., Després J.-P., Fullerton H.J., et al. Executive Summary: Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association. Circulation. 2016;133:447–454. doi: 10.1161/CIR.0000000000000366. - DOI - PubMed
    1. Kostner K.M., Kostner G.M. Lipoprotein (a): A historical appraisal. J. Lipid Res. 2017;58:1–14. doi: 10.1194/jlr.R071571. - DOI - PMC - PubMed
    1. Kamstrup P.R. Lipoprotein(a) and ischemic heart disease—A causal association? A review. Atherosclerosis. 2010;211:15–23. doi: 10.1016/j.atherosclerosis.2009.12.036. - DOI - PubMed
    1. Schmidt K., Noureen A., Kronenberg F., Utermann G. Structure, function, and genetics of lipoprotein (a) J. Lipid Res. 2016;57:1339–1359. doi: 10.1194/jlr.R067314. - DOI - PMC - PubMed
    1. Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Goldberger Z.D., Hahn E.J., Himmelfarb C.D., Khera A., Lloyd-Jones D., McEvoy J.W., et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: A report of the american college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;140:e596–e646. doi: 10.1161/CIR.0000000000000678. - DOI - PMC - PubMed

LinkOut - more resources